877130-28-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one is used as a potential pharmaceutical agent for its possible pharmacological activities. (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one's complex structure, incorporating various functional groups and rings, suggests that it may interact with biological targets in ways that could lead to the development of new therapeutics.
Given the lack of specific application details in the provided materials, the uses listed are speculative and based on the compound's structural features, which are often associated with potential medicinal chemistry applications. Further research would be required to determine the exact applications and efficacy of (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one in various therapeutic areas.

Upstream product

• 55293-96-4 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde 
• 877130-24-0 6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-dihydro-3H-pyran-2,4-dione 
• 1508308-97-1 C₂₉H₃₆⁽²⁾HN₅O₃ 
• 927889-49-4 (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-dihydro-2H-pyran-2,4(3H)-dione 
• 1508318-99-7 C₃₁H₄₀N₂O₅ 
• 1510832-90-2 C₃₁H₄₃N₅O₄ 
• 1510832-87-7 C₃₉H₄₈N₆O₅ 
• 1228897-39-9 C₂₁H₂₉NO₃ 
• 1228897-34-4 C₂₁H₂₉NO₃ 
• 927889-50-7 dibenzoyl-L-tartaric acid salt of (R)-6-cyclopentyl-6-(2,6-diethylpyridin-4-yl)ethyl-4-hydroxy-5,6-dihydropyran-2-one 
• 1510832-89-9 C₂₄H₃₅NO₆ 
• 1510832-88-8 C₂₁H₃₃NO₃ 

Relevant academic research and scientific papers

Synthesis of filibuvir. Part III. Development of a process for the reductive coupling of an aldehyde and a β-keto-lactone

Development of a reductive coupling of a β-keto-lactone and an aldehyde is described, in which the Hantzsch ester serves as an inexpensive and convenient reducing agent. Structural features in the β-keto-lactone rendered standard reductive coupling conditions ineffective, requiring development of a specific addition and temperature protocol. Identification of one of the reactants as Ames positive required a single-digit parts per million control strategy for this impurity in the final active pharmaceutical ingredient (API).

Synthesis of filibuvir. Part II. Second-generation synthesis of a 6,6-disubstituted 2H-pyranone via dieckmann cyclization of a β-acetoxy ester

This paper describes an improved sequence for the conversion of an oxazolidinone (3) to a β-keto lactone (5). The primary drivers behind this change were the modest and variable yields observed in the intramolecular cyclization to generate the β-keto lactone. Changing the cyclization substrate from oxazolidinone to alkyl ester offered a significantly improved cyclization, as well as improvements in the alkyne hydrogenation. Selection of the optimal substrates for methanolysis and intermediate salt formation are also described.

Synthetic route optimization of PF-00868554, an HCV polymerase inhibitor in clinical evaluation

This paper describes the optimization efforts to establish an enabling synthesis to provide multigram quantity of PF-00868554, an HCV polymerase inhibitor currently in phase II clinical evaluations.

Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5, 7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5, 6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor

The HCV RNA-dependent RNA polymerase has emerged as one of the key targets for novel anti-HCV therapy development. Herein, we report the optimization of the dihydropyrone series inhibitors to improve compound aqueous solubility and reduce CYP2D6 inhibitio

METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS

The present invention relates to methods and compounds useful in the preparation of compounds of the formula (I).

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).